In an attempt to better understand the molecular mechanism of action of the antipsychotic lead LASSBio-579 and of its main metabolite LQFM 037, the aim of this work was to evaluate their intrinsic activity and binding kinetics at the dopamine D 2 receptor. In transfected HEK cells expressing the D 2L receptor under an inducible promoter, LASSBio-579 and LQFM 037, but not clozapine, behaved as weak partial agonists in [ 35 S]-GTPγS binding assays performed in optimized conditions previously shown to evidence the partial agonist profile of aripiprazole. Besides, data obtained in radioligand competition assays on rat striatal membranes suggested a rapid association to and dissociation from the D 2 -like receptors. Using the kinetic rate index based on the strategy of the dualpoint competition association assay, we showed that our compounds share a similar kinetic profile with clozapine, distinct from the typical antipsychotic haloperidol. These two characteristics could contribute to the atypical-like profile observed after administration of LASSBio-579 to rodents, in models of positive and negative symptoms of schizophrenia.
Introduction
According to the World Health Organization (WHO, 2014) , schizophrenia is a "severe mental disorder, characterized by profound disruptions in thinking, affecting language, perception, and the sense of self", being characterized by positive and negative symptoms and cognitive dysfunction. The pharmacological treatment of schizophrenia essentially relies on drugs classified as typical and atypical antipsychotics. Typical antipsychotics, as haloperidol and chlorpromazine, are effective against positive symptoms but often cause extrapyramidal side effects and prolactin elevation (Ginovart and Kapur, 2012) . The atypical antipsychotics (e.g. clozapine and risperidone), are also effective against positive symptoms, somewhat more efficacious for improving negative symptoms and are associated with lower incidence of extrapyramidal symptoms (EPS) (Leucht et al., 2009) . Nevertheless, metabolic disturbances including weight gain and hyperlipidemia are major side effects associated with atypical antipsychotics, although a large heterogeneity exists within this class of molecules (Leucht et al., 2009; Patel et al., 2014; Raedler, 2010) . With respect to their mechanism of action, typical and atypical antipsychotics also differ in their receptor binding profiles: typical antipsychotics are considered as relatively pure antagonists of the D 2 receptors, whereas the atypical antipsychotics are usually multitarget drugs acting at the D 2 receptor but also at serotonin, cholinergic and/or adrenergic receptors (Ginovart and Kapur, 2012; Roth et al., 2004) . In fact, the mechanism supporting their atypical profile has not been unveiled, even for clozapine, and could have different backgrounds as suggested by several concepts that have been proposed: dual antagonism at 5-HT 2A and D 2 receptors (Meltzer, 1989) , selective blockade of D 4 receptors (clozapine), partial agonism at 5-HT 1A receptors (Newman-Tancredi and Kleven, 2011) , rapid dissociation (Seeman, 2002) and/or partial agonism (Strange, 2008) at D 2 receptors and inhibition of glycogen synthase kinase-3 (Beaulieu et al., 2009) . Focusing on the D 2 receptor, the "fast-off" theory proposes that atypical drugs are loosely bound and rapidly released from D 2 receptors in the synapse explaining their lower propensity to induce EPS and hyperprolactinemia (Ginovart and Kapur, 2012; Kapur and Seeman, 2000; Seeman, 2002; Vauquelin et al., 2012) . Another property that could explain the atypicality of some antipsychotic is a partial agonism at the D 2 receptor. A weak but significant positive intrinsic activity could reduce the occurrence of extrapyramidal side effects commonly assigned to persistent blockade of striatal D 2 receptors, without decreasing the capacity of reducing the positive symptoms due to a hyperdopaminergic drive in the mesolimbic pathway (Guo et al., 2013; Kapur and Seeman, 2000; Seeman, 2002) .
We previously described (Menegatti et al., 2003 ) the synthesis of LASSBio-579 (1-[1-(4-chlorophenyl)-1H-4pyrazolylmethyl] phenylhexahydropiperazine), that has been elected as a new atypical antipsychotic lead compound based on in vitro and in vivo assays classically used in antipsychotic drug discovery programs. Briefly, oral administration of LASSBio-579 in mice inhibited the apomorphine-induced climbing, ketamine-induced hyperlocomotion and deficit of prepulse inhibition of acoustic startle reflex induced by apomorphine, (±)-DOI and ketamine (Neves et al., 2013) . Our binding studies defined LASSBio-579 as a moderate affinity ligand of D 2 -like/D 4 /5-HT 1A receptors (K i values around 0.2-0.4 μM) with low affinity for the 5-HT 2A receptor (K i around 7 μM) and other receptors putatively involved in atypicality (Neves et al., 2010; Pompeu et al., 2013) . We also identified and synthesized the main metabolite of LASSBio-579 in rats as its phydroxylated derivative (LQFM 037), and reported its binding to the D 2 and D 4 receptors at submicromolar concentrations, indicating that it could participate to the antipsychotic-like effects observed after administration of the parent compound (Gomes et al., 2013) . All these previous in vitro and in vivo promising preclinical results suggest that LASSBio-579 could have antipsychotic effects albeit translating basic research into viable products is particularly difficult in Schizophrenia (Abbott, 2010) .
In an attempt to better understand the molecular mechanism of action of LASSBio-579 and of its main metabolite, the aim of this work was to test the hypothesis of partial agonism and fast-off binding at the dopamine D 2 receptor.
Materials and methods

Radioligands and drugs
Cell culture medium (Dulbecco's Modified Eagle Medium) and G418 (50 mg/mL Stock) were from Gibco-Invitrogen (Merelbeke, Belgium). Bovine serum was purchased from Thermoscientific (Tournai, Belgium ]-YM-09151-2 (82.7 Ci/mmol) were purchased from New England Nuclear Life Science Products, PerkinElmer, USA. All drugs were of high quality. 1-[1-(4-Chlorophenyl)-1H-4-pyrazolylmethyl]-4-phenylhexahydropyperazine (LASSBio-579) and its p-hydroxylated metabolite (LQFM 037) were obtained as described elsewhere (Gomes et al., 2013; Menegatti et al., 2003) . The test substances and (-)-sulpiride were dissolved in DMSO to obtain stock solutions. Subsequent dilutions were prepared in incubation buffer or water. At the final concentration used (0.2% at most), DMSO had no effect in our assays.
Transfected cells and inducible expression
The establishment of an inducible expression system of the D 2L receptor has been previously described in details (Koener et al., 2012) . Cells were routinely maintained in Dulbecco's modified Eagle's medium, supplemented with fetal bovine serum (10% v/v), 1% penicillin-streptomycin (Invitrogen), G418 (250 μg/mL) and hygromycin B (50 μg/mL), at 37°C in 5% CO 2 . For the [ 35 S]-GTPγS binding studies, the cells were plated in 175 cm 2 flask. When approaching confluency, the antibiotics were removed and the cultured medium was supplemented with doxycycline (2 μg/mL) for 48 h and NaBu (5 mM) for 24 h in order to induce a robust expression and high density of the D 2L receptors before harvesting the cells.
Membrane preparations
For [
35 S]-GTPγS binding assays, confluent HeLa cells expressing the D 2L receptor grown with or without (control) doxycycline and NaBu were washed and scraped on ice from the culture flasks with cold phosphate buffered saline (PBS). The cell membranes were prepared as previously described (Koener et al., 2012) and the protein concentration was determined by the method of Bradford (1976) .
For radioligand binding assays (see 2.5.), striatum of adult male Wistar rats were homogenized and centrifuged as previously described . The pellet was resuspended in 20 volumes of buffer and incubated at 37°C during 10 min for removal of endogenous neurotransmitters. This suspension was cooled on ice and ultracentrifuged twice at 48,000 g for 20 min at 4°C. The final pellet was resuspended and stored in liquid nitrogen until use. The protein concentration was determined by the method of Lowry et al., 1951 .
[ 35 S]-GTPγS binding assay
The binding experiments were performed using a binding buffer containing 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 5 mM MgCl 2 , 150 mM NaCl, 10 μM GDP and 1 mM dithiotreitol. When indicated, NaCl was substituted by 100 mM NMDG. The experiment was carried out in deep 96-well plates. Each well contained 30 μg protein, resuspended in a final volume of 500 μL. In all experiments, [
35 S]GTPγS at the final concentration of 0.1 nM was added to each well before initiating the binding by addition of the membrane suspension. The nonspecific binding was measured in the presence of 100 μM Gpp(NH)p. Incubation was performed at 30°C for 40 min and terminated by the addition of 1 mL ice-cold washing buffer (Tris-HCl, pH 7.4, 1 mM EDTA, 5 mM MgCl 2 , with either 150 mM NaCl, or 100 mM NMDG). The suspension was immediately filtered through 96-well plate adapted-GF/B glass fiber filters and the filters processed as previously described (Koener et al., 2012) .
Competition association assay
Binding kinetics of haloperidol, clozapine, LASSBio-579 and LQFM 037 were evaluated using the competition association assay (Motulsky and Mahan, 1983 ) with a single concentration of the unlabeled compounds around their K i values. The assay was initiated by adding 50 μg of striatal membranes in a final volume of 500 μL, under yellow light in a buffer containing Tris-HCl (pH 7.4), NaCl 120 mM, KCl 5 mM, MgCl 2 5 mM, CaCl 2 1.5 mM, EDTA 1 mM with 0.2 nM [ 3 H]-YM-09151-2 at 37°C in the absence or presence of unlabeled compounds. The non-specific binding was estimated using 30 μM (-)-sulpiride. At different time points, samples were rapidly diluted with 3 × 4 mL Tris-HCl 5 mM (pH 7.4) and immediately filtered under vacuum on glass fiber filters (GMF 3, Filtrak, Germany). Filters were then dried, immersed in a scintillation mixture and the radioactivity counted ).
Data analysis
All experimental data were analyzed using GraphPad Prism 5.0 (GraphPad Software, Inc., CA, USA). All values are means of at least three independent experiments performed in triplicate. For the [ 35 S]-GTPγS binding, data were analyzed by non-linear regression using the classical equations for simple concentration-effect curves and competition binding assays. For the competition association assay with [
3 H]-YM-09151-2, data were fitted using the model of one-phase exponential association in order to obtain the half-life values and the maximum binding at equilibrium. For calculation of the kinetic rate index (Guo et al., 2013) we divided the fitted binding at 5 min (Bt 1 ) by the value at 60 min (Bt 2 ), in each experiment. Differences of half-life and kinetic rate index between groups were tested using One way ANOVA followed by Newman-Keuls post-hoc test.
Results
Quantitative evaluation of the intrinsic activity of LASSBio-579, LQFM 037 and clozapine at the D 2L receptor
The intrinsic activity of clozapine and our compounds at the D 2L receptor was estimated using the classical [ 35 S]-GTPγS binding assay in membrane of HELA cells expressing the mouse D 2L receptor. In a conventional buffer containing NaCl, LASSBio-579 and LQFM 037 elicited a modest increase in the specific [ 35 S]-GTPγS binding, with E max values of 14 ± 3.1% and 10.4 ± 4.9%, respectively, while clozapine had no effect (Fig. 1) . On the other hand, in a buffer where NaCl was replaced by NMDG (to eliminate Na + ions while maintaining the osmolarity), (Table 1) . For this purpose, we used each drug at a single high concentration, sufficient to approach the maximal effect. Replacing NaCl by NMDG did not increase the maximum effect of dopamine and apomorphine, two agonists with high efficacy (high E max ). On the other hand, the maximum effect of the weak partial agonists was increased considerably in the absence of Na + ions, as observed for 3-PPP (E max increased approximately 5 times) ( (Table 1) . Taking advantage of the inducible expression system in our model of transfected cells, we also tested the activity of LASSBio-579 and LQFM 037 in cells not exposed to doxycycline and NaBu. As expected, LASSBio-579 and LQFM 037 did not change [ Classically, partial agonism is fully characterized when demonstrating that a drug is able to produce an effect by itself and to partially reduce the effect of a full agonist. In our experimental conditions, antagonism at the D 2L receptor was validated using domperidone. Indeed, domperidone fully blocked the effect of dopamine (1 μM) in a concentration-dependent manner in the two buffers, with a small rightward shift of the concentration-curve when tested in the NMDG buffer that favors the stimulatory effect of dopamine (Fig. 2B) (Fig. 2C) . However, the inhibition was not complete, reducing the response to 25 ± 4% (LASSBio-579) and 11 ± 8% (LQFM 037) of the stimulatory effect of dopamine, even at the highest concentrations of the compounds. This pattern is consistent with the fact that LASSBio-579 and LQFM 037 are partial agonists and in good accordance with their respective levels of intrinsic activity reported in Table 1 . In the NMDG containing buffer, which favors the stimulatory effect not only of dopamine but especially of the weak partial agonists, the antagonism exerted by both LASSBio-579 and LQFM 037 was less obvious, with a shift to the right of the inhibition curves. For this reason, it was not possible to obtain complete curves with these compounds, due to the lack of solubility at higher concentrations. At the highest concentration tested of the compounds (30 μM), the dopamine response was decreased by approximately 35-38% (Fig. 2D) . Together, these results suggest that like aripiprazole and unlike clozapine, LASSBio-579 and LQFM 037 can be considered as weak partial agonists of the D 2L receptor.
Binding kinetics of LASSBio-579, LQFM 037, clozapine and haloperidol to the D 2 -like receptors
Based on the "fast-off" theory for explaining the atypicality of antipsychotic action (Kapur and Seeman, 2000 ; see introduction), we decided to compare the kinetics of binding of our compounds with those of haloperidol and clozapine, as controls for typical and atypical antipsychotics, respectively. As radiolabeled derivatives of LASSBio-579 and LQFM 037 are not available, we decided to adapt the competition association assay described originally by Motulsky and Mahan (1983) using [ 3 H]-YM09151-2, a high-affinity and selective antagonist ligand for the dopamine D 2 receptor. Thus, the kinetic of [ 3 H]-YM09151-2 binding to rat striatal D 2 receptors was determined in the absence and presence of a single concentration of the unlabeled competitors, chosen in order to achieve similar inhibition at equilibrium. Fig. 3 shows the association of the reference radioligand determined in three to seven independent experiments and the curves fitted according to the model of a one phase exponential association. As expected, the time to reach equilibrium (here estimated quantitatively by the half-life (t 1/2 ) was increased in the presence of the competitors (Table 2 ). In addition, a clear difference was observed between haloperidol and clozapine, since clozapine increased more than twice the t 1/2 of [ 3 H]-YM09151-2 binding when compared to the t 1/2 measured in the presence of haloperidol (p b 0.001).
As the concentrations of the competitors were roughly equivalent in terms of effect at equilibrium (% inhibition: 22-39%, see Table 2 ), the NaCl buffer differences in association kinetic reflect differences in binding kinetics of the unlabeled competitors, with higher values indicating rapid association and dissociation. With respect to their effect on [ 3 H]-YM09151-2 binding, our compounds showed great similarity with clozapine, leading to even higher values of t 1/2 , thus very differently from the typical antagonist haloperidol (Table 2 ). Based on the method proposed by Guo et al. (2013) to distinguish compounds with rapid or slow dissociation from the target, we also measured a kinetic rate index. Table 2 shows that the values of this index, obtained by calculating the ratio of binding values measured at 5 min and 60 min, were significantly lower with clozapine than with haloperidol, again supporting a more rapid association and dissociation. This second approach in analyzing the binding kinetics of unlabeled ligands also indicated clearly that LASSBio-579 and LQFM 037 were comparable to clozapine but not to haloperidol for their binding to the D 2 receptor (Table 2) .
Discussion
In the present study, we addressed the question of the molecular mechanism of action of LASSBio-579, a lead compound that we previously reported as having atypical-like properties in rodent models of schizophrenia, and of its main metabolite (LQFM 037). We decided to focus here on two characteristics related to the D 2 receptors, the key target of all antipsychotics used clinically, that could contribute, at least partially, to their reported atypical-like profile in rats.
Intrinsic activity at the D 2 receptor
Firstly, we investigated the intrinsic activity of LASSBio-579 (and of its main metabolite, LQFM 037) at the D 2 receptor based on the hypothesis that partial agonism at this receptor could balance the hyperactive dopaminergic drive in the mesolimbic pathway and the hypoactive drive in the mesocortical pathway, that are considered as hallmarks of schizophrenia (Ginovart and Kapur, 2012; Tamminga, 2002) . Moreover, by avoiding excessive blockade of nigrostriatal D 2 receptors, a partial agonist would have a lower propensity to cause EPS and prolactin elevation (Ginovart and Kapur, 2012; Tamminga, 2002) . This idea gained force with the demonstration that aripiprazole has a distinct mechanism of action (sometimes even elected as a third generation antipsychotic) based on reports indicating that it behaves as a low efficacy partial agonist at the D 2 receptor, effective against positive and negative symptoms without causing EPS and hyperprolactinemia (Burris et al., 2002) . However, the type of assay and experimental conditions are crucial in order to characterize compounds endowed with low intrinsic activity (Jordan et al., 2007; Lin et al., 2006) as also confirmed by our previous work with aripiprazole (Koener et al., 2012) . Using the same protocol, we indeed evidenced an increase in [ 35 S]GTPγS binding with aripiprazole only when using cells with a considerably high expression of the D 2 receptors and when Na + ions were substituted by NMDG in the buffer. These results are in accordance with the literature since it is known that sodium ions disfavor the formation of the ternary complex of GPCRs and that the replacement of Na + ions by NMDG increases the sensitivity for detecting partial agonists with low efficacy (Lin et al., 2006) . The same pattern was observed with our compounds, so that they can also be considered as weak partial agonists of the D 2 receptor. However, one has to be cautious when considering the clinical relevance of this property since some authors reported that the partial agonism of aripiprazole depended on the cell-line and the pathway analyzed, suggesting that the originality of aripiprazole could be due to a functional selective profile at the D 2 receptor (Shapiro et al., 2003; Urban et al., 2007) .
Kinetics of binding at the D 2 receptor
Drug-target residence time, a concept coined by Copeland (Copeland et al., 2006) and in consonance with earlier work on the binding mechanisms of drugs (Swinney, 2004) , has gained much attention in recent drug discovery literature. This concept was initially introduced to point out the advantages of long residence time with respect to duration of effect and target selectivity. On the contrary, in accordance with the "fast-off" theory of atypical antipsychotic action, a loose binding to the D 2 receptor would be beneficial thanks to a rapid dissociation from the receptor and a lower propensity to induce on-target toxicity such as EPS (Guo et al., 2013; Seeman, 2014) . In the case of antipsychotics, a correlation was revealed between high affinity and in vitro low-dissociation rate (direct correlation between K i and k off ) for a series of drugs (Kapur and Seeman, 2000) . In these experiments, clozapine, the more efficacious atypical antipsychotic, dissociated much more rapidly (k off about 80 times higher) than haloperidol, used here as reference typical antipsychotic. Although such low dissociation has been confirmed in recent works, especially for clozapine, quetiapine and olanzapine (Seeman, 2014; Vauquelin et al., 2012) , not all published studies support the "fast-off" theory of atypicality. Sahlholm et al. (2014) , for instance, reported that recovery from clozapine and amisulpride antagonism was less than two fold faster than from chlorpromazine in a functional assay characterized by the presence of continuous buffer flow and of dopamine competition, supposed to prevent antagonist rebinding that can occur in binding dissociation studies (Vauquelin et al., 2012) . However, this kind of highly effective washout of antagonist could also be far from the in vivo situation at the synapse level, where rebinding could occur and contribute to the residence time of the antagonist at the receptor. In order to compare our drugs, not available as radiolabeled ligands, to haloperidol and clozapine, we adapted the competition kinetic assay proposed by Motulsky and Mahan (1983) and measured the binding of [ 3 H]-YM09151-2 at 11 time points, in the absence and presence of a single concentration of the unlabeled competitors. The half-lives of binding indicated that our compounds influenced the radioligand binding kinetics similarly to clozapine but differently from haloperidol. Of note, this protocol was proven useful to discriminate clozapine and haloperidol, with statistical power, and that a higher t 1/2 (clozapine N haloperidol) was expected for a drug dissociating more rapidly. We also used an alternative approach to compare quantitatively the binding kinetics of our unlabeled ligands, based on the strategy of the dual-point competition association validated by Guo et al. (2013) for use in high-throughput screening aiming the discrimination of slowly and rapidly dissociating compounds at the adenosine A 1A receptor. Here too, using the kinetic rate index, our results clearly indicated that our compounds share a similar binding kinetic profile with clozapine, significantly different from the one of haloperidol. Noteworthy, a limitation of our assay was the fact that the radioligand commonly used for binding to the D 2 -like receptors, ) and slowly (haloperidol: k off = 0.017 min − 1 ) dissociating drugs (Kapur and Seeman, 2000) . This explains why when using haloperidol as a slowly dissociating drug we failed to observe the "overshoot" of the time course curve of [ 3 H]-YM09151-2 binding, or a kinetic rate index higher than 1 (Guo et al., 2014) . In fact, as explained by Motulsky and Mahan (1983, Fig . 3A) , the association curve of the radioligand will consist of two phases, starting with a typical "overshoot" and then a decline until a new equilibrium is reached only if the competitor dissociates faster from its target than the radioligand.
Mechanism of atypicality
A priori, the most classical hypothesis for atypicality, higher affinity for 5-HT 2A than for D 2 receptors (Meltzer, 1989) , could not apply to our compounds since they have an inverted selectivity with about 16-18 times more affinity for the D 2 -like receptors than for the 5-HT 2A receptors (Gomes et al., 2013) . Indeed the D 2 /5-HT 2A K i ratios obtained with LASSBio-579 and LQFM 037 in vitro (0.056 and 0.064, respectively) were about 100 times lower than with clozapine (6.5), according to previous data (Gomes et al., 2013) . Furthermore, there are many exceptions to this concept of 5-HT 2A /D 2 relative selectivity for explaining atypicality (Seeman, 2014) as amisulpride, for example, is considered as a very selective antagonist of the D 2 -D 3 receptors lacking affinity for the 5-HT 2A receptors (Natesan et al., 2008) . On the other hand, we cannot rule out a contribution of 5-HT 2A antagonism in vivo, for two reasons: 1. We previously reported that LASSBio-579 reduced the number of head-twitches and ear-scratches induced in mice by (±)DOI, a selective 5-HT 2 agonist (Neves et al., 2008) . 2. It has been shown that brexipiprazole binds with high affinity to both rat D 2 and 5-HT 2A receptors in vivo albeit it has a D 2 /5-HT 2A K i ratio similar to LASSBio-579 (0.092) in vitro (Maeda et al., 2014) .
Conclusion
LASSBio-579 and its main metabolite (LQMF 037) share with aripiprazole, but not clozapine, the property to behave as weak partial agonists at the D 2L receptor, at least in defined experimental conditions. Our compounds also have a binding kinetic profile similar to clozapine in vitro, indicating a rapid dissociation from the target (D 2 ) receptor, at variance with haloperidol. These two characteristics could contribute to the atypical-like profile observed after administration of LASSBio-579 to rodents, in different models of positive and negative symptoms. 
